Clinical Characteristics and Survival in Systemic Sclerosis-Related Pulmonary Hypertension Associated with Interstitial Lung Disease

Chest

Volumn 140, Issue 4, 2011, Pages 1016-1024

  Launay, David ^a,b   Humbert, Marc ^c,d,e   Berezne, Alice ^f   Cottin, Vincent ^g,h   Allanore, Yannick ^f   Couderc, Louis Jean ⁱ   Bletry, Olivier ⁱ   Yaici, Azzedine ^c,d   Hatron, Pierre Yves ^a   Mouthon, Luc ^f   Le Pavec, Jérôme ^b   Clerson, Pierre ^j   Hachulla, Eric ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIV LILLE   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d HÔPITAL ANTOINE BÉCLÈRE   (France)

^e CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g HOSPICES CIVILS DE LYON   (France)

^h UNIVERSITÉ LYON 1   (France)

ⁱ FOCH HOSPITAL   (France)

^j Orgametrie   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE; CENTROMERE ANTIBODY;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FORCED VITAL CAPACITY; HEART CATHETERIZATION; HEMODYNAMICS; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG ARTERY PRESSURE; LUNG DIFFUSION CAPACITY; MALE; MORBIDITY; MORTALITY; PERICARDIAL EFFUSION; PHENOTYPE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; SMOKING; SURVIVAL RATE; SYSTEMIC SCLEROSIS;

EID: 80053530028     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.10-2473     Document Type: Article

References (35)

1. Le Pavec J, Launay D, Mathai SC, et al. Scleroderma lung disease. Clin Rev Allergy Immunol. 2011;40(2):104-116.
2. Launay D, Mouthon L, Hachulla E, et al. Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease. J Rheumatol. 2007;34(5):1005-1011. (Pubitemid 46774846)
3. Mathai SC, Hummers LK, Champion HC, et al. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum. 2009;60(2):569-577.
4. Trad S, Amoura Z, Beigelman C, et al. Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum. 2006;54(1):184-191. (Pubitemid 43122201)
5. Condliffe R, Kiely DG, Peacock AJ, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med. 2009;179(2):151-157.
6. Chang B, Wigley FM, White B, Wise RA. Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. J Rheumatol. 2003;30(11):2398-2405. (Pubitemid 37413900)
7. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54(suppl 1):S43-S54.
8. Minai OA, Chaouat A, Adnot S. Pulmonary hypertension in COPD: epidemiology, significance, and management: pulmonary vascular disease: the global perspective. Chest. 2010;137(suppl 6):39S-51S.
9. Weitzenblum E, Chaouat A, Canuet M, Kessler R. Pulmonary hypertension in chronic obstructive pulmonary disease and interstitial lung diseases. Semin Respir Crit Care Med. 2009;30(4):458-470.
10. Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J. 2008;32(5):1371-1385.
11. Chang B, Schachna L, White B, Wigley FM, Wise RA. Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma. J Rheumatol. 2006;33(2):269-274. (Pubitemid 43209302)
12. Chaouat A, Bugnet AS, Kadaoui N, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;172(2):189-194. (Pubitemid 40981192)
13. Hachulla E, Launay D, Mouthon L, et al French PAH-SSc Network. Is pulmonary arterial hypertension really a late complication of systemic sclerosis? Chest. 2009;136(5):1211-1219.
14. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980;23(5):581-590.
15. LeRoy EC, Medsger TAJ Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol. 2001;28(7):1573-1576. (Pubitemid 32660630)
16. Quanjer PH, Tammeling GJ, Cotes JE, et al. Standardization of the measurements of transfer factor (diffusing capacity). Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993;16(suppl 16):41-52.
17. Launay D, Sitbon O, Le Pavec J, et al. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Rheumatology (Oxford). 2010;49(3):490-500.
18. Campo A, Mathai SC, Le Pavec J, et al. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med. 2010;182(2):252-260.
19. Avouac J, Airo P, Meune C, et al. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheumatol. 2010;37(11):2290-2298.
20. Steen VD, Conte C, Owens GR, Medsger TA Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum. 1994;37(9):1283-1289. (Pubitemid 24320744)
21. Steen VD, Lucas M, Fertig N, Medsger TA Jr. Pulmonary arterial hypertension and severe pulmonary fibrosis in systemic sclerosis patients with a nucleolar antibody. J Rheumatol. 2007;34(11):2230-2235. (Pubitemid 350076884)
22. Talbot NP, Balanos GM, Robbins PA, Dorrington KL. Can intravenous endothelin-1 be used to enhance hypoxic pulmonary vasoconstriction in healthy humans? Br J Anaesth. 2008;101(4):466-472.
23. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hyperten sion in advanced idiopathic pulmonary fibrosis. Chest. 2006;129(3):746-752.
24. Cottin V, Le Pavec J, Prévot G, et al; GERM"O"P. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J. 2010;35(1):105-111.
25. Corte TJ, Wort SJ, Gatzoulis MA, Macdonald P, Hansell DM, Wells AU. Pulmonary vascular resistance predicts early mortality in patients with diffuse fibrotic lung disease and suspected pulmonary hypertension. Thorax. 2009;64(10):883-888.
26. Galiè N, Hoeper MM, Humbert M, et al ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30(20):2493-2537.
27. Dorfmüller P, Montani D, Humbert M. Beyond arterial remodelling: pulmonary venous and cardiac involvement in patients with systemic sclerosis-associated pulmonary arterial hypertension. Eur Respir J. 2010;35(1):6-8.
28. Dorfmüller P, Humbert M, Perros F, et al. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol. 2007;38(6):893-902. (Pubitemid 46735956)
29. Overbeek MJ, Vonk MC, Boonstra A, et al. Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy. Eur Respir J. 2009;34(2):371-379.
30. Montani D, Jaïs X, Dorfmuller P, Simonneau G, Sitbon O, Humbert M. Goal-oriented therapy in pulmonary venoocclusive disease: a word of caution. Eur Respir J. 2009;34(5):1204-1206.
31. Montani D, Achouh L, Sitbon O, Simonneau G, Humbert M. Pulmonary venoocclusive disease and failure of specific therapy. Chest. 2009;136(4):1181.
32. Montani D, Jaïs X, Price LC, et al. Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease. Eur Respir J. 2009;34(6):1348-1356.
33. Provencher S, Sitbon O, Humbert M, Cabrol S, Jaïs X, Simonneau G. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J. 2006;27(5):589-595.
34. Le Pavec J, Girgis RE, Lechtzin N, et al. Systemic sclerosis related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies. Arthritis Rheum. In press.
35. Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008;177(11):1248-1254. (Pubitemid 351860934)